Total amount: € 0,00
HOW TO ORDER
THE JOURNAL OF CARDIOVASCULAR SURGERY
A Journal on Cardiac, Vascular and Thoracic Surgery
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
ORIGINAL ARTICLES THORACIC SECTION
The Journal of Cardiovascular Surgery 2001 June;42(3):415-9
Pericardial catheter sclerosis versus surgical procedures for pericardial effusions in cancer patients
Anderson T. M., Ray C. W. *, Nwogu C. E., Bottiggi A. J., Lenox J. M., Driscoll D. L., Urschel J. D.
From the Department of Thoracic Surgical Oncology
*Division of Radiation Medicine State University of New York & Roswell Park Cancer Institute Buffalo, New York, USA
Background. Approximately 21% of patients with advanced malignancies have cardiac or pericardial involvement with tumor. Controversy exists regarding the optimal approach to the pericardial space when hemodynamic compromise due to effusions occurs.
Methods. A six-year retrospective review of 59 cancer patients with pericardial effusions.
Results. Thirty-six patients had subxiphoid pericardial window (SXPW) alone (Group A), 5 had pericardial catheter drainage (PCD) followed by a SXPW (Group B), 10 had PCD with sclerosis (Group C), 5 had PCD alone (Group D), 2 had PCD with pericardial-pleural window (Group E), and one had pericardial-peritoneal window (Group F). The method of procedure, complications, number of hospital and ICU days, cytological or pathologic evidence of malignancy, solid versus hematological tumors, and survival were analyzed. The median survival for those patients in group C was one month compared to 4 months for Group A and 6 months for Group B. Essentially, results were similar regardless of method performed with the exception that professional and hospital charges averaged $4830 for SXPW compared to $1625 for PCD.
Conclusions. Pericardial catheter drainage and sclerosis provides a viable option for the treatment of pericardial effusions in selected cancer patients at markedly reduced cost and patient discomfort.